A Study of Tirzepatide (LY3298176) Compared With Standard of Care in Adult Participants With Obesity and Without Diabetes (SURMOUNT-REAL UK)
Phase 4 – monitoring after market approval
Conditions:
Obesity
Sponsor: Eli Lilly and Company
trial.available_in:
БГ
Overview
The purpose of this study is to evaluate tirzepatide within a real-world setting to assess body weight loss and incidence of type 2 diabetes in adults without diabetes who have obesity and at least one weight-related comorbid condition. Participation in the study will last about 260 weeks.
Who can participate
Inclusion Criteria:
* Have a body mass index ≥30 and ≤34.9 kilogram per square meter (kg/m2)
* Have an increased waist to height ratio (defined by \>0.5)
* Have at least one weight related comorbid condition
* Have had at least one attempt to lose weight with lifestyle intervention (diet and physical activity)
Exclusion Criteria:
* Have type 1 diabetes, type 2 diabetes, or any other types of diabetes
* Have had a change in body weight of greater than 5 kilograms (11 pounds) within 90 days prior to screening
Interventions
Tirzepatide
DRUG
Standard of Care
OTHER
Locations
30
United Kingdom (30)
P91604 St John's Medical Centre
Altrincham
NOT_YET_RECRUITING
P89008 Ashton Medical Group
Ashton-under-Lyne
Y02319 SSP Bolton General Practice
Bolton
NOT_YET_RECRUITING
P83012 Tower Family Healthcare
Bury
NOT_YET_RECRUITING
P91014 Washway Road Medical Centre
Cheshire
NOT_YET_RECRUITING
P88007 Cheadle Hulme Medical Group (was Cheadle Hulme Health Centre) (Bridge House)
БГ